News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Akhil Santhosh: 1st chemo-VEGF combo to show PFS and OS in platinum-resistant ovarian cancer
rogelcancercenter.org
Feb 4, 2025, 17:11

Akhil Santhosh: 1st chemo-VEGF combo to show PFS and OS in platinum-resistant ovarian cancer

Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post on X about a recent paper by Tiantian Wang et al. published in JAMA Oncology:

“Effect of Apatinib Plus Pegylated Lipodox vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant ca ovary: APPROVE trial.

1st chemo-VEGF combo to show PFS and OS in plat resistant ca ovary, increased toxicities a concern.”

“Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer”

Authors: Tiantian Wang et al.

Akhil Santhosh: 1st chemo-VEGF combo to show PFS and OS in platinum-resistant ovarian cancer

More posts featuring Akhil Santhosh.

Akhil Santhosh APPROVE trial cancer OncoDaily Oncology Tiantian Wang
Special Coverage
Science
Feb 4, 2025, 17:11
Akhil Santhosh: 1st chemo-VEGF combo to show PFS and OS in platinum-resistant ovarian cancer
Societies
Feb 4, 2025, 17:10
ESMO is joining the 156th WHO Executive Board Meeting
Blog
Feb 4, 2025, 17:07
Run for the Alliance - Colorectal Cancer Alliance
Science
Feb 4, 2025, 17:07
Giovanni Marchegiani: Can we make a soft pancreas harder to reduce POPF?
Societies
Feb 4, 2025, 17:05
Rallying support to overcome the hurdles of cancer care costs - Canadian Cancer Society
Insight
Feb 4, 2025, 17:04
Hung Trinh: Oncolytic virus and CAR-T cell therapy in solid tumors
Science
Feb 4, 2025, 17:03
Michael Hofman: 18F-CETO for primary aldosteronism
Blog
Feb 4, 2025, 17:02
Axel S. Merseburger: When would you consider HR clinically meaningful in HRR allcomer population?
Science
Feb 4, 2025, 17:00
Bosutinib-Induced Pleural Effusion—Class Effect and Cross-Intolerance to All Tyrosine Kinase Inhibitors by Nikhil Vojjala et al.
Blog
Feb 4, 2025, 16:59
Luis E Raez: Celebrating the III International thoracic Cancer Debates
Science
Feb 4, 2025, 16:58
A retrospective study in EGFR+ NSCLC with brain metastases - Clinical Lung Cancer
Blog
Feb 4, 2025, 16:57
Julie McCrossin: What lessons has melanoma survivor, Karen van Gorp, learnt about advocacy